Knight is widely considered the partner of choice for Canada. Knight’s senior leadership has a proven track record of success and has successfully collaborated with over 30 companies to structure deals designed to meet partner needs:
• Commercialized over 60 products in Canada
• Grew Canadian revenue to ~$150M and international revenue to ~$120M
• Built sales and marketing teams/expertise across multiple therapeutic areas
• Significant experience in all aspects of the regulatory process
• Over 30 submissions to Health Canada with a 90% success rate
Pricing and Reimbursement
• Extensive experience and success with PMPRB, provincial formularies and private payors
• PMPRB acceptance of all major brands’ launch prices
• Track record in obtaining significant price increases in public markets
• Successfully negotiated favourable listings
We are actively seeking innovative product candidates in all therapeutic areas that will deliver novel solutions to healthcare professionals and patients across Canada.
While we are primarily interested in acquiring the rights to late-stage products, we also will license and acquire differentiated earlier-stage assets that address unmet medical needs.
Rest of World (excluding U.S., Europe, Japan)
Knight is actively looking for potential products and companies that fit within its existing business model, but that are in select areas such as Latin America, Israel, Australia, the Middle-East, Sub-Saharan Africa, and the Caribbean. Knight is interested in acquiring an equity position in companies that are in these high growth countries which are non-core geographies. To discuss partnership opportunities, contact us at email@example.com.
Knight holds a 28.3% ownership interest in Medison, Israel’s leading specialty pharmaceutical and therapeutic device company. Medison is focused on delivering innovative healthcare solutions to the Israeli market, including but not limited to early access programs, government registration and reimbursement, medical affairs, marketing, and logistics. Medison is the exclusive Israeli partner for leading global pharma companies such as Amgen®, Biogen®, Shire® and Ipsen®.
Knight is currently looking for international partners interested in-licensing the rights to the following products:
Neuragen®: Clinically proven to reduce peripheral neuropathic pain quickly and without many of the side effects common with prescription medications
Impavido: For patients with Visceral, Mucosal and Cutaneous Leishmaniasis
Knight is interested in financing life sciences companies with the goal of earning interest income, strengthening relationships in the life sciences industry and securing product distribution rights for Canada and select international markets.
Strategic Fund Investments
Knight is open to investing in life sciences venture capital funds in which we earn a return similar to any other limited partner in the fund and receive preferential access to innovative healthcare products from around the world for Canada and select international markets. To date, we have committed to invest over $125 million with 9 fund managers.